The National Institute for Allergy & Infectious Diseases (NIAID) has an advisory committee that provides input on HIV vaccine research called the AIDS Vaccine Research Subcommittee (AVRS). The AVRS met back in February to discuss the results of the RV144 trial in Thailand and consider their implications for the future of of the field, and specifically for NIAID-supported research efforts. A report summarizing some of the presentations and discussion at the meeting has been posted to the TAG website.
Post a comment
Comments are moderated, and will not appear until the author has approved them.
Your Information
(Name and email address are required. Email address will not be displayed with the comment.)
Comments